Anti-aging polysaccharide GLP-1b in ganoderma lucidum as well as preparation method and application of anti-aging polysaccharide GLP-1b
Through the polysaccharide GLP-1b extracted and prepared from Ganoderma lucidum fruiting entities, the problem that the anti-aging components of Ganoderma lucidum in the prior art has not been effectively explored, and the activation of SIRT1, SIRT3, and SIRT6 enzymes has been achieved, which significantly prolongs healthy lifespan and Significantly anti-aging.
Patent Information
- Application Number
- CN202411067951.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art has failed to effectively detect the anti-aging components in Ganoderma lucidum, especially polysaccharides related to the activation activities of the longevity genes SIRT1, SIRT3, and SIRT6, which has led to insufficient application in the field of anti-aging.
A new Ganoderma lucidum polysaccharide GLP-1b is extracted and prepared from Ganoderma lucidum fruiting entities. This polysaccharide consists of mannose, glucose, galactose and fucose. It has a complex glycosidic bond connection pattern and the main chain is α-D-1 ,6-galactose and α-D-1,2,6-galactose residues, with fucose, mannose and glucose linked to the O-2 position of their main chain, modified by acetylation group, Purification was obtained by methanol extraction, ultrasonic extraction, DEAE-52 column chromatography and Sephadex G-50 column chromatography.
GLP-1b has a significant activation effect on SIRT1, SIRT3 and SIRT6 enzymes, significantly prolongs the body's healthy lifespan, improves mitochondrial function, reduces oxidative stress and inhibits inflammation, and has significant anti-aging effects.
Smart Images

Figure CN118978612A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical technology, and specifically relates to a ganoderma lucidum polysaccharide GLP-1b in ganoderma lucidum, a preparation method thereof, and application thereof in the preparation of cosmetics. Technical Background
[0002] Ganoderma lucidum is one of the most well-known medicinal fungi in my country. It has been used in my country for more than 2,000 years. In the face of the dilemma that the anti-aging ingredients of Ganoderma lucidum have not yet been confirmed, the research on the functions of polysaccharides is heating up again. More than 200 Ganoderma lucidum polysaccharides have been obtained from the fruiting bodies, spores, mycelium and culture medium of Ganoderma lucidum. Their chemical structures have been determined by various analytical methods such as chemical reactions, spectral analysis and chromatography techniques, such as monosaccharide composition, glycosidic bond connection type, branch substitution position, molecular weight and sugar chain conformation. The results show that most Ganoderma lucidum polysaccharides are glucans, heteroglucans, heterogalactans and other heteropolysaccharides composed of glucose, mannose, galactose, xylose, fucose and arabinose. The glucans found in Ganoderma lucidum are mainly β-D-glucans linked by (1→3), (1→4) and (1→6). Studies have shown that β-D-glucans with (1→3)-linked main chains and (1→6)-linked branches are biological response modifiers (BRMs) with immunoenhancing effects. Therefore, some fungi containing β-D-glucans, such as Ganoderma lucidum, are research hotspots in the fields of natural medicine and functional foods. Some scholars used a simple ethanol precipitation method to obtain a homogeneous glucan GLP20 from Ganoderma lucidum fruiting bodies, and the molecular weight was determined to be 2.42×106g / mol using HPSEC-MALLS-RI. Its structure contains β-(1→6)-branched β-(1→3)-D-glucan with a branching degree (DB) of about 0.33, and exists in a triple helical conformation in aqueous solution. The structures of several glucans in Ganoderma lucidum spores are more complex than those in fruiting bodies. They usually contain combinations of α or β glucose, including (1→3)-α-D-glucan, (1→4)-α-D-glucan with branched β-D-glucan backbone, (1→3)-β-D-glucan with branched β-D-glucan backbone, (1→6)-β-D-glucan with branched β-D-glucan backbone, and α and β-D-glucan at the same time. A large number of pharmacological experiments have shown that the significant anti-cancer effect of Ganoderma lucidum polysaccharide is related to its improvement of the body's immunity. Researchers believe that the enhancement of the body's immune function is the core mechanism of anti-tumor. The antioxidant, anti-inflammatory, anti-aging and anti-diabetic biological effects of Ganoderma lucidum are all related to the immunomodulatory function of Ganoderma lucidum polysaccharide. However, the correlation with the anti-aging effect is limited. To this end, this study combined some recent research results and found Ganoderma lucidum polysaccharides with anti-aging activity in the activity screening of activating autophagy and longevity genes SIRTs. It is believed that the active substances that improve mitochondrial function, reduce oxidative stress and inhibit inflammation should be the anti-aging components of Ganoderma lucidum. Sirtuins (SIRTs) are a class of evolutionarily highly conserved NAD+-dependent histone deacylases that participate in the regulation of many biological processes in prokaryotes and eukaryotes, including DNA damage repair, cell metabolism, mitochondrial function and inflammation. Therefore, mammalian sirtuins are considered to be key regulators of cell function and healthy lifespan.There are seven recognized members in the human SIRTs family, namely SIRT1-SIRT7; SIRT6 is recognized as a longevity gene.
[0003] SIRT1 affects skin photoaging, chronological aging, and oxidative stress response. At the skin organ level, SIRT1 can promote the proliferation and differentiation of keratinocytes; SIRT1 can also improve the aging of human skin fibroblasts caused by ultraviolet radiation by inhibiting the activity of matrix metalloproteinases and reducing collagen degradation, and prevent photoaging caused by UVA and UVB. SIRT3 can maintain skin homeostasis by regulating oxidative stress, including oxidative stress caused by environmental factors, and its gene polymorphism is related to aging. Overexpressed SIRT6 regulates in the liver (promoting liver metabolism, reducing inflammatory response, and ensuring liver NAD + It is driven by both the liver function (levels) and the extrahepatic mechanism (glycerol release from adipose tissue), ultimately helping the body fight the signs of aging and maintain youthful energy homeostasis, thereby significantly extending the body's healthy lifespan.
[0004] Therefore, the inventors have recently studied the activation activity of the longevity gene SIRT1, SIRT3, and SIRT6 enzymes of Ganoderma lucidum polysaccharides. In the activity experiment of longevity gene SIRT1, SIRT3, and SIRT6 enzyme inhibition, a Ganoderma lucidum polysaccharide GLP-1b that has not been described was found. It has an activation effect on the three enzymes SIRT1, SIRT3, and SIRT6. It is also a rare polysaccharide in Ganoderma lucidum polysaccharides that has a broad-spectrum activation effect on the SIRTs family, and its structure is much more complex than that of previous Ganoderma lucidum polysaccharides. For this reason, the preparation technology and structural characterization of the preparation technology were studied. Summary of the invention
[0005] The purpose of the present invention is to provide a Ganoderma lucidum polysaccharide GLP-1b, a preparation method thereof, a pharmaceutical composition containing the same, and its use in the preparation of anti-aging drugs and in the preparation of cosmetics in view of the fact that there is no report on Ganoderma lucidum polysaccharide GLP-1b in the prior art.
[0006] In order to achieve the above-mentioned object of the present invention, the present invention provides the following technical solutions:
[0007] Ganoderma lucidum polysaccharide GLP-1b has a structure shown in the following general formula I:
[0008]
[0009] In formula (I), n represents the number of sugar repeating units, and n is a natural number.
[0010] According to the Ganoderma lucidum polysaccharide GLP-1b, the weight average molecular weight of the polysaccharide is 17.77kDa, the number average molecular weight is 14.13kDa, and the dispersion coefficient is 1.26; the polysaccharide is composed of mannose, glucose, galactose and fucose, and the molar ratio is 1.0:1.0:9.5:3.9: it has a complex glycosidic bond connection pattern, mainly including T-fucose, T-mannose, T-glucose, 6-galactose and 2,6-galactose; the main chain is α-D-1,6-galactose and α-D-1,2,6-galactose residues, with fucose, mannose and glucose connected to the O-2 position of its main chain, and extended to GLP-1b modified by acetylated groups.
[0011] The preparation method of Ganoderma lucidum polysaccharide GLP-1b comprises the following steps: crushing a Ganoderma lucidum fruiting body sample into coarse powder, extracting with methanol at 50°C for 5 hours according to a solid-liquid ratio of 1:10 to remove small molecules and pigment components, repeating this step three times, naturally air-drying the residue after extraction, adding deionized water at a solid-liquid ratio of 1:20, performing ultrasonic extraction at 50°C for 1 hour, repeating the same step three times, combining the extracts and drying under reduced pressure to obtain a dry sample; dissolving the dry sample in deionized water, gradually adding anhydrous ethanol, and The alcohol concentrations reached 40%, 60% and 80% respectively, and after being stored at 4°C for 24 hours, they were centrifuged to obtain 40% alcohol precipitate G-40, 60% alcohol precipitate G-60, and 80% alcohol precipitate G-80 respectively; G-60 was dissolved in deionized water, chromatographed using a DEAE-52 column, and eluted with 0, 0.1, 0.3 and 0.5M NaCl solutions in sequence to obtain four components GL-1, GL-2, GL-3, and GL-4 respectively; GL-1 was further purified by Sephadex G-50 column chromatography, the mobile phase was 0.1M NaCl solution, and the flow rate was 0.18 ml / min. The purified components were dialyzed with a molecular weight cutoff of 3.5kDa and freeze-dried to obtain the target polysaccharide component GLP-1b.
[0012] The application of the Ganoderma lucidum polysaccharide GLP-1b in the preparation of anti-aging drugs.
[0013] The application of the Ganoderma lucidum polysaccharide GLP-1b in the preparation of cosmetics.
[0014] A pharmaceutical composition containing the ganoderma lucidum polysaccharide GLP-1b is composed of an effective amount of anti-aging polysaccharide GLP-1b and a pharmaceutical excipient or flavoring agent or excipient or gelling agent.
[0015] The application of the pharmaceutical composition in the preparation of anti-aging drugs.
[0016] The preparation method of the pharmaceutical composition comprises the following steps: crushing the Ganoderma lucidum fruiting body and spore powder samples thereof into coarse powder, extracting with methanol at a solid-liquid ratio of 1:10 at 50°C for 5 hours to remove small molecules and pigment components, repeating this step three times, naturally air-drying the residue after extraction, adding deionized water at a solid-liquid ratio of 1:20, performing ultrasonic extraction at 50°C for 1 hour, repeating the same step three times, combining the extracts and drying under reduced pressure to obtain a dry sample; dissolving the dry sample in deionized water, gradually adding anhydrous ethanol to make the alcohol concentration reach 4 0%, 60% and 80%, stored at 4°C for 24 hours and then centrifuged to obtain 40% alcohol precipitate G-40, 60% alcohol precipitate G-60, and 80% alcohol precipitate G-80, respectively; G-60 was dissolved in deionized water, chromatographed using a DEAE-52 column, and eluted with 0, 0.1, 0.3 and 0.5M NaCl solutions in sequence to obtain four components GL-1, GL-2, GL-3, and GL-4, respectively; GL-1 was further purified by Sephadex G-50 column chromatography, the mobile phase was 0.1M NaCl solution, the flow rate was 0.18 ml / min, the purified components were dialyzed with a molecular weight cutoff of 3.5 kDa and freeze-dried to obtain the target polysaccharide component GLP-1b; however, a pharmaceutical excipient was added.
[0017] A cosmetic containing the ganoderma lucidum polysaccharide GLP-1b is composed of an effective amount of ganoderma lucidum polysaccharide GLP-1b and common cosmetic auxiliary materials.
[0018] When the Ganoderma lucidum polysaccharide GLP-1b described in the present invention is used to prepare medicines or cosmetics, the content of Ganoderma lucidum polysaccharide GLP-1b accounts for 0.1-99% of the mass of the active ingredient, preferably 0.5-90% of the active ingredient, and the rest are pharmaceutical excipients or carriers that are acceptable in pharmacology and pharmaceutical science and non-toxic to humans and animals.
[0019] The preparations are in various dosage forms that can be used clinically, such as capsules, granules, pills, tablets, injections, ointments, tinctures, oral liquids, etc. The dosage forms of the pharmaceutical composition are lyophilized powders, oral liquids, and capsules, etc. The dosage forms of the cosmetics are creams, facial masks, and hydrogels, etc.
[0020] The present invention discovers for the first time from Ganoderma lucidum the active Ganoderma lucidum polysaccharide GLP-1b which has an activating effect on the longevity gene SIRT1, SIRT3, and SIRT6 enzymes, and is one of the relatively significant active components among many Ganoderma lucidum anti-aging polysaccharides. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The preparation process flow chart of Ganoderma lucidum polysaccharide GLP-1b;
[0022] Figure 2HPLC analysis of the monosaccharide composition of GLP-1b polysaccharide from Ganoderma lucidum;
[0023] Figure 3 HPGPC analysis chart of Ganoderma lucidum polysaccharide GLP-1b;
[0024] Figure 4 The ultraviolet analysis spectrum and infrared analysis spectrum of Ganoderma lucidum polysaccharide GLP-1b, wherein: A is the ultraviolet analysis spectrum of Ganoderma lucidum polysaccharide GLP-1b, and B is the infrared analysis spectrum of Ganoderma lucidum polysaccharide GLP-1b;
[0025] Figure 5 GC-MS analysis of Ganoderma lucidum polysaccharide GLP-1b;
[0026] Figure 6 UHPLC-QTOF-MS total ion current spectrum of oligosaccharides after hydrolysis of Ganoderma lucidum polysaccharide GLP-1b and secondary mass spectrometry fragmentation spectrum of peak 2 (DP 9), wherein: A is the UHPLC-QTOF-MS total ion current spectrum of oligosaccharides after hydrolysis of Ganoderma lucidum polysaccharide GLP-1b, and B is the secondary mass spectrometry fragmentation spectrum of peak 2 (DP 9).
[0027] Figure 7 Ganoderma lucidum polysaccharide 1 H NMR spectra and 13 C NMR spectrum, where A is Ganoderma lucidum polysaccharide 1 H NMR spectrum, B is 13 CNMR spectrum.
[0028] Figure 8 Schematic diagram of the putative structural formula of Ganoderma lucidum polysaccharide GLP-1b. DETAILED DESCRIPTION
[0029] The substantial content of the present invention is further described below with reference to the accompanying drawings using embodiments of the present invention, but the content of the present invention is not limited thereto.
[0030] Example 1
[0031] 1. Preparation of polysaccharide component GLP-1b.
[0032] The specific separation steps for extracting and purifying polysaccharides from a 1.8 kg sample of Ganoderma lucidum fruiting body are as follows: 1) The sample is crushed into coarse powder, extracted with methanol at 50°C for 5 hours according to a solid-liquid ratio of 1:10 to remove small molecules and pigment components, and this step is repeated three times. 2) After the residue after extraction is naturally air-dried, deionized water is added according to a solid-liquid ratio of 1:20, and ultrasonic extraction is performed at 50°C for 1 hour, which is also repeated three times. The extracts are combined and dried under reduced pressure to obtain 54 grams of dry sample. 3) The dry sample is dissolved in 300 ml of deionized water, and anhydrous ethanol is gradually added to make the alcohol concentration reach 40%, 60% and 80% respectively. After being stored at 4°C for 24 hours, centrifugation is performed to obtain 4.08 grams of 40% alcohol precipitate (G-40), 7.75 grams of 60% alcohol precipitate (G-60), and 7.00 grams of 80% alcohol precipitate (G-80), respectively. 4) 7.75 g of G-60 was dissolved in 30 ml of deionized water, chromatographed using a DEAE-52 column, and eluted with 0, 0.1, 0.3 and 0.5 M NaCl solutions in sequence to obtain four components (GL-1, GL-2, GL-3, GL-4). 5) GL-1 (3.1 g) was further purified by Sephadex G-50 column chromatography, with a mobile phase of 0.1 M NaCl solution at a flow rate of 0.18 ml / min. 6) The purified components were dialyzed with a molecular weight cutoff of 3.5 kDa and freeze-dried to obtain the target polysaccharide component GLP-1b (0.16 g).
[0033] Preparation process:
[0034] According to the experimental summary and the separation process of the above-mentioned target active molecules, the preparation process of the active polysaccharide GLP-1b in Ganoderma lucidum is summarized as follows: Figure 1 .
[0035] 2. Structural characterization of the target active molecule anti-aging polysaccharide GLP-1b.
[0036] Analysis of GLP-1b monosaccharide composition.
[0037] In order to analyze the monosaccharide composition and molar ratio of GLP-1b, GLP-1b was subjected to acid hydrolysis and PMP derivatization, and then high performance liquid chromatography (HPLC) analysis was performed. The HPLC analysis results showed that the monosaccharides of GLP-1b were composed of mannose, glucose, galactose and fucose, and the corresponding molar ratio was 1.0:1.0:9.5:3.9 (see Figure 2 ). This indicates that galactose is the main component in GLP-1b, while mannose, glucose and fucose are present in smaller proportions.
[0038] GLP-1b molecular weight determination and UV spectroscopy analysis.
[0039] The determination of the molecular weight of GLP-1b usually adopts high performance gel permeation chromatography (HPGPC) technology. HPGPC is a technology commonly used to separate and analyze macromolecules. The molecular weight is estimated by measuring the retention time of the sample in the stationary phase. This method has high resolution and high precision, and is suitable for the analysis of macromolecules such as proteins and polysaccharides. In the determination of the molecular weight of GLP-1b, HPGPC-RID (differential refractive index detector) is used for analysis. During the analysis, the sample is compared with dextran standard substances of known different molecular weights to determine its molecular weight. The experimental results show that the retention time of GLP-1b is 19.45min. According to the comparison of the retention time with the standard substance, the weight average molecular weight (Mw) of GLP-1b is 17.77kDa, the number average molecular weight (Mn) is 14.13kDa, and the dispersion coefficient (PDI=Mw / Mn) is 1.26. Mw is greater than Mn, indicating that there are some molecules with larger molecular weight in the sample; the dispersion coefficient of 1.26 indicates that the molecular weight distribution of the GLP-1b sample is relatively uniform. In addition, the HPGPC chromatogram ( Figure 3 ) shows that GLP-1b is a homogeneous polysaccharide. The inset in the figure shows the molecular weight distribution diagram and the cumulative distribution diagram, making the molecular weight distribution of the sample more intuitive.
[0040] GLP-1b UV and IR spectroscopic analysis.
[0041] The UV spectrum of GLP-1b shows no significant absorption at 260nm and 280nm ( Figure 4 A), indicating that the sample does not contain protein and nucleic acid impurities. In addition, in the wavelength range above 300nm, the absorption intensity is low or there is no absorption, which is consistent with the ultraviolet absorption characteristics of polysaccharides and confirms the polysaccharide nature of GLP-1b.
[0042] The main absorption peaks in the FTIR spectrum of GLP-1b are shown in Figure 4Middle B: A strong and broad absorption peak was observed at 3432cm-1, which was attributed to the stretching vibration of the hydroxyl (OH), which is a common characteristic absorption peak in polysaccharide molecules, indicating that there are a large number of hydroxyl groups in GLP-1b. The absorption peak at 2929cm-1 is attributed to the stretching vibration of the CH group, especially the vibration of the CH2 and CH3 groups, which is common in the polysaccharide structure. The weaker absorption peak at 1725cm-1 is usually attributed to the stretching vibration of the carbonyl (C=O) group, indicating that GLP-1b may contain a small amount of esters or other carbonyl compounds. The absorption peak at 1648cm-1 is attributed to water absorption or the stretching vibration of the C=O group, which is related to the hygroscopicity of the polysaccharide. The absorption peaks at 1542cm-1 and 1409cm-1 are attributed to the bending vibration of the CH2 and CH3 groups, further supporting the carbon-hydrogen bond characteristics in the polysaccharide structure. The absorption peak at 1354cm-1 is attributed to the bending vibration of the CH3 group, which is common in the side chain structure of polysaccharides, further indicating that the fucose contained in the monosaccharide composition analysis should be the side chain of GLP-1b. The absorption peak at 1254cm-1 indicates the presence of stretching vibration of the COC group, suggesting the presence of ether bonds in GLP-1b. The strong absorption peak at 1149cm-1 is attributed to COC stretching vibration, which is the characteristic peak of glycosidic bonds in polysaccharides. The strong absorption peaks at 1076cm-1 and 1032cm-1 are attributed to C-OH and COC stretching vibrations, further confirming the glycosidic bonds and alcohol groups in the polysaccharide structure. In addition, the absorption peaks at 976cm-1, 874cm-1, and 769cm-1 are generally attributed to the bending vibration and deformation vibration of the sugar ring, indicating the presence of α-D-pyranose in the sample. The lower wavenumber absorption peaks at 687cm-1 and 563cm-1 are also attributed to the bending and deformation vibrations of the sugar ring.
[0043] GLP-1b methylation analysis.
[0044] The methylation analysis of GLP-1b, GLP-1bⅠ and GLP-1bⅡ samples by GC-MS revealed the detailed glycosidic bond connection sites of their polysaccharides. The 6,6'-dideuterated sugars generated by NaBD4 reduction labeling resulted in a mass increase of M+2, while the 6,6'-dihydrosugars generated by NaBH4 reduction labeling only resulted in a mass increase of M. These structural features are used to determine whether GLP-1b contains acidic sugars. The results showed that the mass-to-charge ratios (m / z) of the same ion peaks identified in GLP-1b, GLP-1bⅠ and GLP-1bⅡ samples were similar, indicating that the glycosidic bond connection sites of these samples were consistent. These results further indicated that GLP-1b did not contain acidic sugars, thus verifying the conclusions of monosaccharide analysis. The results of infrared spectroscopy (IR) analysis showed that GLP-1b may contain a small amount of ester compounds, which may bind to GLP-1b polysaccharides through acetylation modification, resulting in a weaker absorption peak at 1725cm-1 in the IR spectrum. GC-MS analysis revealed the composition and glycosidic bond pattern of GLP-1b. The main partially methylated sugar alcohol acetyl ester derivatives are as follows: 2,3,4-Me3-Fucp, 2,3,4,6-Me4-Manp, 2,3,4,6-Me4-Glcp, 2,3,4-Me3-Galp, 3,4-Me2-Galp, with corresponding molar ratios of 5.01:1.00:1.31:24.96:7.65 (see Table 1). The main mass fragments (m / z) of these partially methylated alditol acetyl ester derivatives are: 59.0, 72.0, 88.0, 102.0, 118.0, 131.0, 175.0 (T-Fucp), 59.0, 87.0, 102.0, 118.0, 129.0, 145.0, 162.0, 205.0 (T-Manp), 59.0, 87.0, 102.0, 118.0, 131.0, 175.0 (T-Fucp), 59.0, 87.0, 102.0, 118.0, 129.0, 145.0, 162.0, 205.0 (T-Manp). 0, 129.0, 145.1, 162.0, 205.1 (T-Glcp), 59.0, 71.1, 87.0, 99.0, 118.0, 129.0, 159.0, 189.0, 233.1 (→6) Galp (1→), and 60.0, 74.1, 87.0, 100.0, 130.0, 190.0, 233.0 (→2,6) Galp (1→), see Figure 5 These results indicate that GLP-1b has a complex polysaccharide structure, and the molar percentage of (1→→6)Galp is 62.51%, indicating that 1,6-Galp may constitute its main chain.
[0045] Table 1 GC-MS analysis results of methylated sugar alcohol acetyl ester derivatives of GLP-1b samples
[0046]
[0047] GLP-1b oligosaccharide sequence analysis.
[0048] UHPLC-QTOF-MS analysis of oligosaccharides derived from GLP-1b after weak acid hydrolysis showed that its oligosaccharides were mainly composed of α-1,6-linked galactose (Gal) units. Total ion chromatogram ( Figure 6 Figure (A) shows 12 ion peaks, and the molecular weights of peaks 1-10 differ by 162Da. Combined with the analysis of methylation and monosaccharide composition, it can be inferred that these peaks represent oligosaccharide fragments connected to α-1,6-galactose (Gal) with different degrees of polymerization (DP 1 to 10). This increasing relationship and change in peak area further confirm that the main chain of GLP-1b is composed of α-1,6-galactose residues. According to previous studies, the retention time of isomeric sugars on the chromatographic column will be different after being derivatized with ABEE, and the m / z of Peak 10' is 330.1556, which is the same as the m / z of Peak 10, indicating that peak 10' may be an ABEE derivative of glucose and mannose. The m / z of Peak 11' is 476.2131, which is attributed to T-Fuc connected to the 2-O position of the α-1,2,6-galactose residue. Secondary mass spectrum ( Figure 6 Middle B) The secondary mass spectra of peak 2 at different energy levels (DP 6) were further analyzed. The main fragment ions include m / z 330.1566 (DP1), 492.2043 (DP 2), 654.2584 (DP 3), 816.3061 (DP 4), 978.3691 (DP 5), 1140.4208 (DP6), 1302.4661 (DP 7), 1464.518 (DP 8) and 1626.5726 (DP 9). These fragments clearly show the cleavage process of gradually removing a sugar unit. These results not only reveal the complex structure of GLP-1b polysaccharide, but also show the changes in oligosaccharide fragments after ABEE derivatization, providing strong evidence for the determination of the main chain of GLP-1b.
[0049] GLP-1b NMR analysis.
[0050] In order to further analyze the refined structure of GLP-1b, the present invention uses one-dimensional nuclear magnetic resonance (1D NMR) spectroscopy technology. Figure 7 A shows the 1D of GLP-1b 1 H NMR spectrum, Figure 7 Middle B shows 1D 13 C NMR spectrum. 1In the H NMR spectrum, multiple chemical shift signals were observed, especially in the region of 4.89 ppm to 5.04 ppm, and the signals corresponding to 4.89 ppm corresponded to →6)-α-D-galactose residues, 4.88 ppm corresponded to →6)-α-D-galactose-(OAc) residues, 4.97 ppm corresponded to →2,6)-α-D-galactose-(OAc) residues, 4.98 ppm corresponded to →2,6)-α-D-galactose residues, 5.04 ppm corresponded to α-L-fucose residues, 5.04 ppm corresponded to α-L-fucose-(OAc) residues, 5.00 ppm corresponded to α-D-glucose residues, and 5.01 ppm corresponded to α-D-mannose (Man) residues. 13 In the C NMR spectrum, the chemical shift of the corresponding terminal carbon is in the range of 97.8ppm to 101.3ppm. These data further confirm that the main chain of GLP-1b is composed of α-D-1,6-galactose and α-D-1,2,6-galactose residues, and fucose, mannose and glucose are connected to the O-2 position of the main chain as the end. In addition, GLP-1b is also modified by acetylation groups, which is crucial to its biological activity. The deduced structure of GLP-1b is shown in Figure 8 .
[0051] in conclusion
[0052] The above studies have proved that a new homogeneous polysaccharide of galactose residues modified by acetylated groups as the main chain of galactose glucomannan was found in Ganoderma lucidum fruiting bodies. It was fully characterized by a series of analytical methods. The molecular weight determination results showed that the weight average molecular weight (Mw) of the polysaccharide was 17.77kDa, the number average molecular weight (Mn) was 14.13kDa, and the dispersion index (PDI) was 1.26. The monosaccharide composition analysis showed that the polysaccharide was composed of mannose, glucose, galactose and fucose with a molar ratio of 1.0:1.0:9.5:3.9. The methylation analysis results revealed its complex glycosidic bond connection pattern, mainly including T-fucose, T-mannose, T-glucose, 6-galactose and 2,6-galactose. Its structural features were further confirmed by NMR spectroscopy analysis, which included multiple characteristic chemical shift signals indicating that the main chain was composed of α-D-1,6-galactose and α-D-1,2,6-galactose residues with fucose, mannose, and glucose attached to the O-2 position of its main chain.
[0053] Example 2
[0054] Screening of the activity of Ganoderma lucidum polysaccharide GLP-1b in activating SIRTs.
[0055] 1) Experimental principle
[0056] SIRTs are specific deacetylases, and SIRT1, SIRT3, and SIRT6 can specifically catalyze the deacetylation of different substrates. Therefore, this series of experiments uses specific peptides that are simultaneously connected to fluorescent groups and fluorescent quenching groups as substrates, allowing the test compounds to react with different SIRTs enzymes, specific substrates, and NAD + After co-incubation, the quenching group of the deacetylated substrate is specifically removed using a termination colorimetric agent. The degree of deacetylation of the substrate can be quantified by detecting the fluorescence intensity, thereby calculating the effect of the test compound on the activity of SIRTs. The reaction principle is as follows:
[0057]
[0058] 2) Experimental methods
[0059] 1. Dissolve the reaction substrate peptide and NAD+ in Tris-HCl buffer at pH 8.0 to prepare a reaction substrate solution of appropriate concentration.
[0060] 2. Set up 100% initial activity wells, blank wells, and test sample wells. For the 100% initial activity wells, add 25 μL of reaction buffer, 5 μL of SIRTs enzyme solution, and 5 μL of solvent (the same solvent used to dissolve the test sample); for the blank wells, add 30 μL of reaction buffer and 5 μL of solvent (the same solvent used to dissolve the test sample); for the test sample wells, add 25 μL of reaction buffer, 5 μL of SIRTs enzyme solution, and 5 μL of the test sample.
[0061] 3. Add 15 μL of substrate solution to all wells to start the reaction. Cover the microplate and incubate on a shaker at room temperature for 45 minutes.
[0062] 4. Then, add 50 μL of stop color reagent to each well and incubate at room temperature for 30 minutes.
[0063] 5. After the incubation, remove the plate cover and read the fluorescence intensity using a fluorescence microplate reader with an excitation wavelength of 350-360 nm (480-500 nm for SIRT6) and an emission wavelength of 450-465 nm (520-540 nm for SIRT6).
[0064] 6. Calculation of results:
[0065]
[0066] 3) Experimental results of Ganoderma lucidum polysaccharide GLP-1b on the enzyme activation activity of longevity genes SIRT1, SIRT3, and SIRT6.
[0067] The detection concentration of the sample to be tested is 200μg / mL.
[0068] The activity test results of the samples to be tested are:
[0069] Table 2 Experimental results of Ganoderma lucidum polysaccharide GLP-1b on the activation activity of longevity genes SIRT1, SIRT3, and SIRT6 enzymes
[0070]
[0071] Note: “Rate<0” represents an increase in enzyme activity; “Rate>0” represents an inhibition of enzyme activity.
[0072] From the above experimental data of the longevity gene SRITs enzyme inhibition activity, it can be seen that GLP-1b, a polysaccharide of Ganoderma lucidum, has activation activity on longevity gene SIRT1, SIRT3, and SIRT6 enzymes, and the activation activity is greater than 20%. Most of the Ganoderma lucidum polysaccharides separated and purified by the inventor have the activity of inhibiting SIRT1, SIRT3, and SIRT6 enzymes, while only a small part has an activation effect on longevity gene SIRT1, SIRT3, and SIRT6 enzymes, and only has an activation effect on one of the SIRTn enzymes. Therefore, it is unique that GLP-1b has activation activity on longevity gene SIRT1, SIRT3, and SIRT6 enzymes, while a large amount of Ganoderma lucidum is woody parts, and there are very few polysaccharides and secondary metabolites. The active site GL-1 is about 0.18%, which is already very high and has development value. The new discovery that GLP-1b, a polysaccharide of Ganoderma lucidum, has activation activity on longevity gene SIRT1, SIRT3, and SIRT6 enzymes is of extraordinary significance for revealing the magical effects of enzymes related to Ganoderma lucidum longevity genes.
[0073] Example 3
[0074] Preparation of Ganoderma lucidum polysaccharide GLP-1b freeze-dried powder injection.
[0075] 1. Materials
[0076] Ganoderma lucidum polysaccharide GLP-1b obtained by the same method as Example 1, pharmaceutical grade sodium chloride.
[0077] 2. Prescription
[0078]
[0079] 3. Preparation process
[0080] Weigh the prescribed amount of Ganoderma lucidum polysaccharide GLP-1b and sodium chloride, add injection water to the full amount, stir to dissolve completely, and sterilize by intermittent hot pressing. Add 0.3% medicinal activated carbon and stir for 20 minutes; use a Buchner funnel and a 3.0μm microporous filter membrane to remove the heat source by decarbonization filtration. After the content is qualified, filter with a 0.22μm microporous filter membrane; divide into controlled vials, 0.5mL per bottle, half-stopper, place in a freeze drying box, freeze-dry according to the set freeze-drying curve, stopper, unbox, roll cap, visually inspect and package to obtain the finished product.
[0081] Freeze-drying process: put the sample into the box, lower the partition temperature to -40℃, keep it for 4 hours; lower the cold trap to -50℃, and start to evacuate to 250μbar. Start sublimation: uniformly increase the temperature to -20℃ in 1 hour, keep it for 3 hours; uniformly increase the temperature to -10℃ in 3 hours, keep it for 8 hours, and keep the vacuum at 100~250μbar; then dry: increase the temperature to -5℃ in 2 hours, keep it for 2 hours, and keep the vacuum at 150~200μbar; increase the temperature to 10℃ in 0.5 hours, keep it for 2 hours, and keep the vacuum at 80~100μbar; increase the temperature to 40℃ in 0.5 hours, keep it for 4 hours, and evacuate to the lowest vacuum.
[0082] Example 4
[0083] Preparation of Ganoderma lucidum polysaccharide GLP-1b oral solution.
[0084] 1. Materials
[0085] The Ganoderma lucidum polysaccharide GLP-1b is obtained in the same manner as in Example 1, and the food or pharmaceutical grade flavoring agent is and caramel flavor.
[0086] 2. Prescription
[0087]
[0088] 3. Preparation process
[0089] Weigh the prescribed amount of Ganoderma lucidum polysaccharide GLP-1b, sucrose and caramel essence, add purified water to completely dissolve, filter through a 0.22 μm microporous filter membrane, fill the filtrate into 2 mL per bottle through an oral liquid filling machine, seal and sterilize to obtain the product.
[0090] Example 5
[0091] Preparation of Ganoderma lucidum polysaccharide GLP-1b capsules.
[0092] 1. Materials
[0093] The Ganoderma lucidum polysaccharide GLP-1b and food or medicinal grade starch are obtained in the same manner as in Example 1.
[0094] 2. Prescription
[0095]
[0096] 3. Preparation process
[0097] Weigh the prescribed amount of Ganoderma lucidum polysaccharide GLP-1b and starch, stir to mix thoroughly, add appropriate amount of talcum powder, wet granulate with ethanol, sieve and dry, and then fill into No. 2 capsule shells, with each capsule body filled with 60 mg of Ganoderma lucidum polysaccharide GLP-1b, to prepare Ganoderma lucidum polysaccharide GLP-1b capsules.
[0098] Example 6
[0099] Preparation of Ganoderma lucidum polysaccharide GLP-1b facial mask.
[0100] 1. Materials
[0101] The Ganoderma lucidum polysaccharide GLP-1b was obtained in the same manner as in Example 1, and other materials were cosmetic grade or food grade raw materials.
[0102] 2. Formulation
[0103] Ganoderma lucidum polysaccharide GLP-1b12 g, xanthan gum 3.5 g, hydrolyzed hyaluronic acid 2.0 g, sodium hyaluronate 2.0 g, propylene glycol 0.3 g, carbomer 0.5 g, paraben 0.1, PPG-10 methyl glucose ether 0.25 g, glyceryl glucoside 1.0 g, deionized water 45 g.
[0104] 3. Mask preparation process
[0105] Step 1: Add deionized water, xanthan gum, hydrolyzed hyaluronic acid, sodium hyaluronate, propylene glycol, carbomer and paraben into an emulsifier and heat to 75°C while stirring. After reaching the temperature, keep warm and continue stirring until the solution is transparent and uniform. Then keep warm for 20 minutes and then cool down to 42°C.
[0106] Step 2: Adjust pH = 7.6 ± 0.2.
[0107] Step 3: Continue to cool to 35°C, add PPG-10 methyl glucose ether, Ganoderma lucidum polysaccharide GLP-1b, and glycerol glucoside, continue to stir evenly, and discharge after passing the inspection. Coating is performed on a non-woven fabric substrate with a coating amount of 2.1 g per square centimeter.
[0108] Example 7
[0109] Preparation of Ganoderma lucidum polysaccharide GLP-1b facial cleanser.
[0110] 1. Materials
[0111] The Ganoderma lucidum polysaccharide GLP-1b is obtained in the same manner as in Example 1, using cosmetic grade or food grade raw materials.
[0112] 2. Formulation
[0113] Ganoderma lucidum polysaccharide GLP-1b 7g, glycerin 2.0g, butylene glycol 4.0g, propylene glycol 0.5g, sodium EDTA 0.1g, guar gum 0.3g, zinc dioxide 2.0g, C12-15 alcohol benzoate 4.0g, C12-20 alkyl glucoside 3.0g, C14-22 alcohol 0.5g, cetearyl alcohol 1.2g, paraben 0.2g, sodium stearate 0.3g, dimethicone 0.5g, polysorbate 0.2g, deionized water 55g.
[0114] 3. Preparation process
[0115] Weigh the prescribed amount of GLP-1b polysaccharide from Ganoderma lucidum, add purified water to completely dissolve it; take glycerol, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 benzoate, C12-20 alkyl glucoside, C14-22 alcohol, cetearyl alcohol, add purified water to completely dissolve it; take paraben, polydimethylsiloxane alcohol, polysorbate, add purified water to completely dissolve it. Mix the above-prepared solutions, stir them evenly, filter them with a 0.22μm microporous membrane, and can the filtrate in 30mL bottles, seal them and sterilize them.
[0116] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0117] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. Ganoderma lucidum polysaccharide GLP-1b having a structure represented by the following general formula (I), In formula (I), n represents the number of sugar repeating units, and n is a natural number.
2. The Ganoderma lucidum polysaccharide GLP-1b according to claim 1, It is characterized in that The weight average molecular weight of the polysaccharide is 17.77 kDa, the number average molecular weight is 14.13 kDa, and the dispersion coefficient is 1.26; the polysaccharide is composed of mannose, glucose, galactose and fucose with a molar ratio of 1.0:1.0:9.5:3.9: it has a complex glycosidic bond connection pattern, mainly including T-fucose, T-mannose, T-glucose, 6-galactose and 2,6-galactose; the main chain is α-D-1,6-galactose and α-D-1,2,6-galactose residues, with fucose, mannose and glucose connected to the O-2 position of its main chain, and extended to GLP-1b modified by acetylated groups.
3. The method for preparing the Ganoderma lucidum polysaccharide GLP-1b according to any one of claims 1 to 2, It is characterized in that The method comprises the following steps: crushing a Ganoderma lucidum fruiting body and a spore powder sample thereof into coarse powder, extracting with methanol at a solid-liquid ratio of 1:10 for 5 hours at 50°C to remove small molecules and pigment components, repeating this step three times, naturally air-drying the residue after extraction, adding deionized water at a solid-liquid ratio of 1:20, performing ultrasonic extraction at 50°C for 1 hour, repeating the same step three times, combining the extracts and drying under reduced pressure to obtain a dry sample; dissolving the dry sample in deionized water, gradually adding anhydrous ethanol to make the alcohol concentration reach 40%, 60% and 80% respectively, storing at 4°C for 24 hours, centrifuging, and obtaining 40% alcohol precipitate G-40, 60% alcohol precipitate G-60, and 80% alcohol precipitate G-80 respectively; dissolving G-60 in deionized water, using DEAE-52 column chromatography, and sequentially using 0, 0.1, 0.3 and 0.5 M After elution with NaCl solution, four components GL-1, GL-2, GL-3, and GL-4 were obtained respectively; GL-1 was further purified by Sephadex G-50 column chromatography with a mobile phase of 0.1 M NaCl solution at a flow rate of 0.18 ml / min. The purified components were dialyzed with a molecular weight cutoff of 3.5 kDa and freeze-dried to obtain the target polysaccharide component GLP-1b.
4. Use of the Ganoderma lucidum polysaccharide GLP-1b according to any one of claims 1 to 2 in the preparation of anti-aging drugs.
5. Use of the Ganoderma lucidum polysaccharide GLP-1b according to any one of claims 1 to 2 in the preparation of cosmetics.
6. A pharmaceutical composition containing the Ganoderma lucidum polysaccharide GLP-1b according to any one of claims 1 to 2, It is characterized in that The pharmaceutical composition is composed of an effective amount of ganoderma lucidum polysaccharide GLP-1b, and a pharmaceutical excipient or flavoring agent or excipient or gelling agent.
7. Use of the pharmaceutical composition according to claim 6 in the preparation of anti-aging drugs.
8. A method for preparing the pharmaceutical composition according to claim 6, It is characterized in that The method comprises the following steps: crushing a Ganoderma lucidum fruiting body and a spore powder sample thereof into coarse powder, extracting with methanol at a solid-liquid ratio of 1:10 for 5 hours at 50°C to remove small molecules and pigment components, repeating this step three times, naturally air-drying the residue after extraction, adding deionized water at a solid-liquid ratio of 1:20, performing ultrasonic extraction at 50°C for 1 hour, repeating the same step three times, combining the extracts and drying under reduced pressure to obtain a dry sample; dissolving the dry sample in deionized water, gradually adding anhydrous ethanol to make the alcohol concentration reach 40%, 60% and 80% respectively, storing at 4°C for 24 hours, centrifuging, and obtaining 40% alcohol precipitate G-40, 60% alcohol precipitate G-60, and 80% alcohol precipitate G-80 respectively; dissolving G-60 in deionized water, using DEAE-52 column chromatography, and sequentially using 0, 0.1, 0.3 and 0.5 M After elution with NaCl solution, four components GL-1, GL-2, GL-3, and GL-4 were obtained respectively; GL-1 was further purified by Sephadex G-50 column chromatography with a mobile phase of 0.1 M NaCl solution at a flow rate of 0.18 ml / min. The purified components were dialyzed with a molecular weight cutoff of 3.5 kDa and freeze-dried to obtain the target polysaccharide component GLP-1b; however, a pharmaceutical excipient was added.
9. A cosmetic containing the Ganoderma lucidum polysaccharide GLP-1b according to any one of claims 1 to 2, It is characterized in that The cosmetics are composed of an effective amount of ganoderma lucidum polysaccharide GLP-1b and common cosmetic auxiliary materials.
